» Articles » PMID: 33211145

MRI-Based Radiomics Nomogram for Differentiation of Benign and Malignant Lesions of the Parotid Gland

Overview
Journal Eur Radiol
Specialty Radiology
Date 2020 Nov 19
PMID 33211145
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Preoperative differentiation between benign parotid gland tumors (BPGT) and malignant parotid gland tumors (MPGT) is important for treatment decisions. The purpose of this study was to develop and validate an MRI-based radiomics nomogram for the preoperative differentiation of BPGT from MPGT.

Methods: A total of 115 patients (80 in training set and 35 in external validation set) with BPGT (n = 60) or MPGT (n = 55) were enrolled. Radiomics features were extracted from T1-weighted and fat-saturated T2-weighted images. A radiomics signature model and a radiomics score (Rad-score) were constructed and calculated. A clinical-factors model was built based on demographics and MRI findings. A radiomics nomogram model combining the Rad-score and independent clinical factors was constructed using multivariate logistic regression analysis. The diagnostic performance of the three models was evaluated and validated using ROC curves on the training and validation datasets.

Results: Seventeen features from MR images were used to build the radiomics signature. The radiomics nomogram incorporating the clinical factors and radiomics signature had an AUC value of 0.952 in the training set and 0.938 in the validation set. Decision curve analysis showed that the nomogram outperformed the clinical-factors model in terms of clinical usefulness.

Conclusions: The above-described radiomics nomogram performed well for differentiating BPGT from MPGT, and may help in the clinical decision-making process.

Key Points: • Differential diagnosis between BPGT and MPGT is rather difficult by conventional imaging modalities. • A radiomics nomogram integrated with the radiomics signature, clinical data, and MRI features facilitates differentiation of BPGT from MPGT with improved diagnostic efficacy.

Citing Articles

The Role of MRI Radiomics Using T2-Weighted Images and the Apparent Diffusion Coefficient Map for Discriminating Between Warthin's Tumors and Malignant Parotid Gland Tumors.

Donci D, Solomon C, Baciut M, Dinu C, Stoia S, Rusu G Cancers (Basel). 2025; 17(4).

PMID: 40002215 PMC: 11852730. DOI: 10.3390/cancers17040620.


Computed tomography enterography-based radiomics for assessing mucosal healing in patients with small bowel Crohn's disease.

Ding H, Fang Y, Fan W, Zhang C, Wang S, Hu J World J Gastroenterol. 2025; 31(3):102283.

PMID: 39839900 PMC: 11684157. DOI: 10.3748/wjg.v31.i3.102283.


An MRI-based radiomics nomogram for preoperative prediction of Ki-67 index in nasopharyngeal carcinoma: a two-center study.

Wang Y, Zhang J, Li Q, Sun L, Zheng Y, Gao C Front Oncol. 2025; 14:1423304.

PMID: 39759139 PMC: 11695239. DOI: 10.3389/fonc.2024.1423304.


Radiomic and Clinical Model in the Prognostic Evaluation of Adenoid Cystic Carcinoma of the Head and Neck.

Rondi P, Tomasoni M, Cunha B, Rampinelli V, Bossi P, Guerini A Cancers (Basel). 2024; 16(23).

PMID: 39682115 PMC: 11640122. DOI: 10.3390/cancers16233926.


MRI-based radiomics machine learning model to differentiate non-clear cell renal cell carcinoma from benign renal tumors.

Wang R, Zhong L, Zhu P, Pan X, Chen L, Zhou J Eur J Radiol Open. 2024; 13:100608.

PMID: 39525508 PMC: 11550165. DOI: 10.1016/j.ejro.2024.100608.


References
1.
Bussu F, Parrilla C, Rizzo D, Almadori G, Paludetti G, Galli J . Clinical approach and treatment of benign and malignant parotid masses, personal experience. Acta Otorhinolaryngol Ital. 2011; 31(3):135-43. PMC: 3185824. View

2.
Mansour N, Bas M, Stock K, Strassen U, Hofauer B, Knopf A . Multimodal Ultrasonographic Pathway of Parotid Gland Lesions. Ultraschall Med. 2015; 38(2):166-173. DOI: 10.1055/s-0035-1553267. View

3.
Fruehwald-Pallamar J, Hesselink J, Mafee M, Holzer-Fruehwald L, Czerny C, Mayerhoefer M . Texture-Based Analysis of 100 MR Examinations of Head and Neck Tumors - Is It Possible to Discriminate Between Benign and Malignant Masses in a Multicenter Trial?. Rofo. 2015; 188(2):195-202. DOI: 10.1055/s-0041-106066. View